JP2015522589A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522589A5
JP2015522589A5 JP2015520305A JP2015520305A JP2015522589A5 JP 2015522589 A5 JP2015522589 A5 JP 2015522589A5 JP 2015520305 A JP2015520305 A JP 2015520305A JP 2015520305 A JP2015520305 A JP 2015520305A JP 2015522589 A5 JP2015522589 A5 JP 2015522589A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
salt
compound according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522589A (ja
JP6114824B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/046685 external-priority patent/WO2014004230A1/en
Publication of JP2015522589A publication Critical patent/JP2015522589A/ja
Publication of JP2015522589A5 publication Critical patent/JP2015522589A5/ja
Application granted granted Critical
Publication of JP6114824B2 publication Critical patent/JP6114824B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520305A 2012-06-29 2013-06-20 ジメチル安息香酸化合物 Active JP6114824B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665956P 2012-06-29 2012-06-29
US61/665,956 2012-06-29
US201361778969P 2013-03-13 2013-03-13
US61/778,969 2013-03-13
PCT/US2013/046685 WO2014004230A1 (en) 2012-06-29 2013-06-20 Dimethyl-benzoic acid compounds

Publications (3)

Publication Number Publication Date
JP2015522589A JP2015522589A (ja) 2015-08-06
JP2015522589A5 true JP2015522589A5 (enExample) 2016-08-04
JP6114824B2 JP6114824B2 (ja) 2017-04-12

Family

ID=48746667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520305A Active JP6114824B2 (ja) 2012-06-29 2013-06-20 ジメチル安息香酸化合物

Country Status (40)

Country Link
US (2) US8642768B2 (enExample)
EP (1) EP2867218B1 (enExample)
JP (1) JP6114824B2 (enExample)
KR (1) KR101634032B1 (enExample)
CN (1) CN104334540B (enExample)
AP (1) AP4063A (enExample)
AR (1) AR091431A1 (enExample)
AU (1) AU2013280779B2 (enExample)
BR (1) BR112014029551A2 (enExample)
CA (1) CA2875572C (enExample)
CL (1) CL2014003537A1 (enExample)
CO (1) CO7160064A2 (enExample)
CR (1) CR20140554A (enExample)
CY (1) CY1118830T1 (enExample)
DK (1) DK2867218T3 (enExample)
DO (1) DOP2014000286A (enExample)
EA (1) EA025531B1 (enExample)
ES (1) ES2623099T3 (enExample)
GT (1) GT201400289A (enExample)
HR (1) HRP20170540T1 (enExample)
HU (1) HUE032398T2 (enExample)
IL (1) IL236218A (enExample)
IN (1) IN2014MN02356A (enExample)
JO (1) JO3221B1 (enExample)
LT (1) LT2867218T (enExample)
ME (1) ME02655B (enExample)
MX (1) MX347476B (enExample)
MY (1) MY172860A (enExample)
NZ (1) NZ701894A (enExample)
PE (1) PE20150185A1 (enExample)
PH (1) PH12015500008B1 (enExample)
PL (1) PL2867218T3 (enExample)
PT (1) PT2867218T (enExample)
RS (1) RS55756B1 (enExample)
SG (1) SG11201408629QA (enExample)
SI (1) SI2867218T1 (enExample)
TN (1) TN2014000500A1 (enExample)
TW (1) TWI572597B (enExample)
WO (1) WO2014004230A1 (enExample)
ZA (1) ZA201408631B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
JP6200596B2 (ja) 2013-12-17 2017-09-20 イーライ リリー アンド カンパニー ジメチル安息香酸化合物
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PE20191616A1 (es) * 2017-04-10 2019-11-05 Bayer Ag N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
JP2000355551A (ja) * 1999-06-15 2000-12-26 Nikken Chem Co Ltd 医薬組成物
MXPA06003123A (es) 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
CA2654811A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
KR20090122931A (ko) * 2007-03-26 2009-12-01 아스테라스 세이야쿠 가부시키가이샤 오르니틴 유도체
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
CA2831978A1 (en) 2011-03-03 2012-09-07 Universitat Des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物

Similar Documents

Publication Publication Date Title
JP2016536286A5 (enExample)
JP2015522018A5 (enExample)
JP2014525470A5 (enExample)
JP2016518437A5 (enExample)
JP2016522254A5 (enExample)
JP2014518266A5 (enExample)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2017514910A5 (enExample)
EA201790088A1 (ru) Ингибиторы syk
RU2012140185A (ru) Ингибирование ангиогенеза
JP2016501221A5 (enExample)
EA201290882A1 (ru) Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
JP2016525102A5 (enExample)
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
JP2012513416A5 (enExample)
JP2019516739A5 (enExample)
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
WO2014153203A3 (en) Alkyl-amine harmine derivatives for promoting bone growth
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2014530818A5 (enExample)
JP2015509075A5 (enExample)
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья
RU2018113718A (ru) Новые соединения
JP2015193630A5 (enExample)
JP2016539157A5 (enExample)